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Abstract
Recent years have confirmed the ubiquitous applicability of lateral flow assays (LFA) in point-of-care testing (POCT). To 
make this technology available for low abundance analytes, strategies towards lower limits of detections (LOD), while 
maintaining the LFA’s ease of use, are still being sought. Here, we demonstrate how liposomes can significantly improve 
the LOD of traditional gold nanoparticle (AuNP)–based assays while fully supporting a ready-to-use system for com-
mercial application. We fine-tuned liposomes towards photometric and fluorescence performance on the synthesis level 
and applied them in an established interleukin 6 (IL-6) immunoassay normally using commercial AuNP labels. IL-6’s low 
abundance (< 10 pg  mL−1) and increasing relevance as prognostic marker for infections make it an ideal model analyte. It 
was found that liposomes with a high encapsulant load (150 mmol  L−1 sulforhodamine B (SRB)) easily outperform AuNPs 
in photometric LFAs. Specifically, liposomes with 350 nm in diameter yield a lower LOD even in complex matrices such as 
human serum below the clinically relevant range (7 pg  mL−1) beating AuNP by over an order of magnitude (81 pg  mL−1). 
When dehydrated on the strip, liposomes maintained their signal performance for over a year even when stored at ambient 
temperature and indicate extraordinary stability of up to 8 years when stored as liquid. Whereas no LOD improvement was 
obtained by exploiting the liposomes’ fluorescence, an extraordinary gain in signal intensity was achieved upon lysis which 
is a promising feature for high-resolution and low-cost detection devices. Minimizing the procedural steps by inherently 
fluorescent liposomes, however, is not feasible. Finally, liposomes are ready for commercial applications as they are easy to 
mass-produce and can simply be substituted for the ubiquitously used AuNPs in the POCT market.
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Introduction
Not only the global pandemic in 2020 emphasized the need 
and relevance of simple, fast, sensitive, and one-site point-
of-care (POC) solution in the medical diagnostic field, but 
also a market size of USD 29 billion in 2020 (which is 
estimated to rise to USD 67 billion in 2026, www. repor tsand 
data. com) [1] depicts its global interest. In this fast-growing 
market, lateral flow assays (LFA) belong to the major game-
players, as they are typically very fast and offer low costs 
and straightforward operation even by non-experts [2]. Aside 
from the numerous benefits of LFAs, such as amenability to 
inexpensive mass production, autonomy of additional exter-
nal equipment, and optical readout, in its simplest form with 
the human eye, standard LFA platforms still have to face 
limitations with regard to sensitivity due to their mostly 
semi-quantitative nature and often provide users only with 
yes/no answers. A lateral flow assay is typically conducted 
in either a competitive or sandwich assay format [3]. Here, 
the test strip consists of a test line typically utilizing a bio-
molecule directed against the analyte as a capture probe and 
a control line which is directed against the reporter particle. 
The sample is added to the sample pad and resolubilizes 
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the reporter particles such as gold nanoparticles (AuNP) or 
colored latex beads from the subsequent conjugate pad along 
its capillary force–driven flow throughout the test strip [4]. 
Depending on the applied format, the analyte-reporter com-
plex binds to the test line yielding an increasing signal with 
increasing analyte concentration in a sandwich assay format. 
The test strip consists of various porous materials with each 
having its unique feature, i.e., assisting in sample transport, 
containment, and homogenous release of reagents, ensuring 
homogenous fluid flow, and capturing relevant biomolecules 
through capture probes via precise test line manufacturing. 
This general design of the LFA allows vast room for sen-
sitivity enhancement at several stages of the LFA devel-
opment. Bishop and colleagues [4] critically assessed the 
adjusting screws which have recently been studied to push 
the development and potential of lateral flow assays towards 
sensitivity levels similar to those of laboratory-based test 
systems. Especially, the applied reagents and envisioned 
reactions and their realization on an LFA were thoroughly 
discussed. Key factors for enhancing the sensitivity of an 
LFA by several orders of magnitude are the development of 
high-affinity reagents, tweak of transport dynamics for ideal 
reaction kinetics as well as label and detection optimization 
of conventional reporter particles, or even integration of sig-
nal amplification strategies [4]. Ultimately, investigating a 
combination of these individual strategies is of special inter-
est. In this study, we focused on the reporter particles and 
signal amplification strategies by exchanging conventional 
AuNP with fluorescent dye–loaded liposomes. Liposomes 
are mainly known as delivery vehicles in medicine and phar-
macology but paved their way into analytical and bioanalyti-
cal applications as detection particles due to their compara-
bly high surface area, a large internal volume, and flexible 
surface modification with various biorecognition elements 
[5, 6]. IL-6 is an important biomarker for immune response 
and inflammatory processes in the human body. It belongs 
to the class of pro-inflammatory cytokines currently under 
evaluation inter alia as a potential biomarker to identify 
COVID-19 positive patients who are at risk of respiratory 
failure and death due to severe inflammatory response [7, 8]. 
Its growing diagnostic relevance as a prognostic marker for 
infections, especially due to COVID-19, and its presence in 
low pg  mL−1 concentrations in serum [9] (in healthy sub-
jects < 10 pg  mL−1) make it an ideal candidate for this study. 
We herein study sulforhodamine B (SRB)–loaded liposomes 
with different sizes in a sandwich-based LFA for the detec-
tion of interleukin 6 (IL-6) in direct comparison to conven-
tional AuNP. These liposomes were synthesized entrapping 
SRB, a highly water-soluble fluorescent dye allowing encap-
sulation of e.g. up to 1.2 million molecules of a 150 mmol 
 L−1 dye solution in a single 300 nm liposome [6] enabling 
visual and fluorescence readout possibilities when applied 
to an LFA [10]. The accompanied signal amplification and 
their double readout feature rise interest in these liposomes 
for ultrasensitive detection in lateral flow assays. Although 
these particles have been applied to lateral flow assays pre-
viously [10–14], these publications only exploit the colori-
metric readout possibility of liposomes focusing on the aca-
demic point of view, as the fluorescence of SRB is quenched 
in intact liposomes. The flexible nature of liposomes with 
regard to encapsulated dye, size, and surface modification 
gives additional advantages over standard AuNP such as e.g. 
multiplexing. We herein demonstrate the evolution of these 
liposomes to commercially ready detection particles and the 
gain in sensitivity by applying liposomes with optimized 
size in direct comparison to a commercial standard AuNP 
approach and designed for colorimetric and fluorescence 
readout. Sensitivity improvement by one order of magni-
tude was already obtained for the colorimetric readout with 
350nm-sized liposomes whereas fluorescence measurement 
can significantly enhance the resolution due to an extraordi-
nary gain in signal intensity. In addition, we show that our 
protein-modified liposomes remain highly stable for long-
term storage in solution and also when dehydrated to the 
conjugate pad for a ready-to-use LFA. This renders the here 
demonstrated IL-6 liposome–based LFAs as a model system 
for any AuNP-based LFA that requires significantly lower 
LODs to become relevant as POCTs.
Experimental section
Chemicals and consumables All chemicals were commercial 
analytical reagent grade and were used without purification. 
Phospholipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocho-
line (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-
rac-glycerol) (sodium salt) (DPPG), and 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-(glutaryl) (sodium 
salt) (N-glutaryl-DPPE), 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine-N-(biotinyl) (sodium salt) (biotinyl-DPPE) 
were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA); 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES), purity > 99.5%, was purchased from VWR 
chemicals (Germany). Sulforhodamine B (SRB) (230162, 
75%) and N-hydroxysuccinimide (NHS) were purchased 
from Sigma-Aldrich/Merck (Germany). Fetal bovine serum 
(FBS) (10270–106) was purchased from ThermoFisher 
Scientific (Germany), and human serum (HS) was provided 
by Microcoat Biotechnology GmbH (Bernried, Germany). 
2-(N-morpholino)ethanesulfonic acid (MES) and bovine 
serum albumin (BSA) (T844.2) were obtained from Carl 
Roth (Karlsruhe, Germany). Custom-made lateral flow test 
strips as well as anti-digoxigenin and anti-IL-6 conjugates 
were kindly provided by Microcoat Biotechnology GmbH 
(Bernried, Germany) as well as recombinant human IL-6 
(200–06, Peprotech, Germany), sheep anti-digoxigenin Fab 
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(11214667001 (Roche) Sigma-Aldrich, Germany), LFA run-
ning buffer (Art. No. 850003) and LFA 5 X serum buffer 
(ESS-2913). For all experiments, ultrapure water was used. 
A more detailed list of standard chemicals and consumable 
is given in the SI.
Synthesis of sulforhodamine B liposomes Liposomes, con-
taining sulforhodamine B, with 6 mol% carboxy function-
alization, were prepared according to an established protocol 
from Edwards et al. [15] with slight adjustments. Shortly, 
encapsulant was prepared by dissolving sulforhodamine B 
(150 mmol  L−1) in 4.5 mL 0.02 mmol  L−1 HEPES buffer, 
pH 7.5. DPPC (29.58 mg, 40.3 µmol), DPPG (15.64 mg, 
21.0 µmol), cholesterol (19.99 mg, 51.7 µmol) and N-glutaryl-
DPPE (6.2 mg, 7.0 µmol) were dissolved in 3 mL chloroform 
and 0.5 mL methanol and thoroughly sonicated in an ultra-
sonic bath (VWR ultrasonic cleaner, model USC 300 THD) 
at 60 °C. Subsequently, 2 mL of preheated (60 °C) encapsu-
lant was added to the lipid solution and emulsified for 4 min 
at 60 °C, using an ultrasonic bath. After emulsification, the 
residual solvent was evaporated at 60 °C under reduced pres-
sure. The remaining 2 mL of encapsulant was added after 
gradual evaporation to 780 mbar and thoroughly vortexed 
before evaporation was continued to 400 mbar. The remain-
ing solution was extruded at 60 °C successively through 
1.0 µm, 0.4 µm, and 0.2 µm membrane using a mini extruder 
(Avanti Polar Lipids, Inc.) to obtain unilamellar liposomes. 
Purification was first performed by size-exclusion chroma-
tography with Sephadex® G-50 as stationary phase (column 
size: 2 cm × 8 cm) and HSS buffer (10 mmol  L−1 HEPES, 
200 mmol   L−1 sodium chloride, 200 mmol   L−1 sucrose, 
0.01 wt% sodium azide), pH 7.5, osmolality 0.643 osmol  kg−1 
as mobile phase. Additionally, the liposomes were dialyzed 
against HSS buffer until the dialysis buffer remains colorless, 
pH 7.5, osmolality 0.643 osmol  kg−1 before the determination 
of the hydrodynamic diameter via DLS, phospholipid concen-
tration via ICP-OES, and zeta potential was done.
Dynamic light scattering (DLS) and ζ‑potential measure‑
ments Dynamic light scattering (DLS) and ζ-potential 
measurements were done on a Malvern Zetasizer Nano-ZS 
(Malvern Panalytical, Germany). For all measurements, the 
temperature was set to 25 °C. Size determination was done 
in semi-micropolymethyl methacrylate (PMMA) cuvettes 
(Brand, Germany), and ζ-potential was done in disposable 
folded capillary zeta cells (Malvern Panalytical, Germany). 
The liposomes were diluted at 1:100 and measured in HSS 
buffer with the following settings: refractive index (RI) of 
the material of 1.34, material absorbance of zero, and RI of 
1.342 of the dispersant viscosity of 1.1185 mPa s applied for 
DLS. For ζ-potential, a refractive index of 1.342, a viscos-
ity of 1.1185 mPa s, and a dielectric constant of 78.5 were 
used. An equilibration time of 60 s was applied before each 
measurement.
Phospholipid concentration Phospholipid concentration 
was determined through inductively coupled plasma opti-
cal emission spectrometer (ICP-OES) measurements with 
a SPECTROBLUE TI/EOP (SPECTRO Analytical Instru-
ments GmbH, Kleve, Germany). Phosphorous was detected 
at 177.495 nm and the device calibrated between 0 and 
100 µmol  L−1 phosphorous in 0.5 mol  L−1  HNO3. Before 
each measurement, the device was recalibrated with 0.5 mol 
 L−1  HNO3 and 50 µmol  L−1 phosphorous. A 1:150 dilu-
tion of the liposomes (3 mL) in 0.5 mol  L−1  HNO3 was 
measured. ICP-OES measurements yielded a phospholipid 
concentration of 6.7 ± 0.04 mmol  L−1.
Protein coupling to liposomes The N-glutaryl modified 
liposomes were mixed with EDC (10 mg  mL−1 in 0.05 M 
MES buffer, pH 5.5) and NHS (10 mg  mL−1 in 0.05 M MES 
buffer, pH 5.5) and incubated for 1 h at room temperature 
(RT) while shaking. The respective equivalent of protein 
(1 mg  mL−1 in PBS) was added and incubated for 1.5 h at 
RT while shaking. A ratio of 1:17:42:0.017 (n(COOH):n(E
DC):n(NHS):n(protein)) was applied for antibody coupling. 
For streptavidin, a ratio of 1:100:180:0.23 was used. Lysine-
HCl (1 mol  L−1 in ultrapure water) was added to yield a final 
concentration of 10 mmol  L−1 and again incubated for at least 
10 min at RT while shaking to quench the reaction. The conju-
gated liposomes were purified via size exclusion chromatog-
raphy using Sepharose CL-4B as stationary phase and HSS 
buffer (10 mmol  L−1 HEPES, 200 mmol  L−1 sodium chloride, 
200 mmol  L−1 sucrose, 0.01 wt% sodium azide), pH 7.5 as 
mobile phase, and a flow rate of approximately 0.5 mL  min−1. 
The conjugates were subsequently characterized by optical 
density, hydrodynamic diameter, and zeta potential measure-
ments. Optical density was measured at 565 nm of a 1:100 
dilution in demineralized water. DLS and zeta potential meas-
urements were done on a Malvern Zetasizer Nano-ZS (Mal-
vern Panalytical, Germany). For all measurements, the tem-
perature was set to 25 °C. The liposomes were diluted 1:500 
in demineralized water and measured with the following 
settings: refractive index (RI) of the material of 1.45, mate-
rial absorbance of 0.001, and RI of 1.330 of the dispersant 
viscosity of 0.8872 mPa s applied for DLS. For ζ-potential, a 
refractive index of 1.330, a viscosity of 0.8872 mPa s, and a 
dielectric constant of 78.5 were used. An equilibration time 
of 60 s was applied before each measurement.
Lateral flow assay procedure The LFA with all reagents in 
solution was performed according to the following procedure 
if not stated differently. Thirty-six microliters of the respec-
tive dilution of recombinant IL-6 in serum and 9 µL serum 
buffer were mixed with 5 µL detection solution consisting of 
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detection particles (colloidal gold and 350 nm liposomes (30 
mOD per test), 190 nm liposomes (40 mOD per test)) and 
anti-IL-6 IgG-biotin (50 ng per test) and incubated 5 min at 
RT in a 2 mL reaction vessel prior to application on the test 
strip. After 15 min, the test strip was evaluated with a ESE-
Quant LFR strip reader. The test strip consists of a transpar-
ent backed CN150 (colloidal gold and 190 nm liposomes) or 
CN95 (350 nm liposomes) nitrocellulose membrane (Sarto-
rius, Göttingen, Germany) with a streptavidin (SA) test line 
(27 mm) and an anti-mouse IgG control line (36 mm). The 
LFA with the reagent solution applied on the test strip was 
done by adding the reagent solution (5 µL detection particles 
(colloidal gold and 350 nm liposomes (30 mOD per test), 
190 nm liposomes (40 mOD per test)) and anti-IL-6 IgG-biotin 
(50 ng per test) to the overlap of sample pad and conjugate pad 
and placed directly into 45 µL IL-6 dilution including 9 µL 
serum buffer. The LFA was allowed to run for 15 min and was 
evaluated photometrically directly after the test run or allowed 
to dry before lysis with 2 µL absolute ethanol for fluorescence 
evaluation. Photometric detection was done directly after a 
test run λmax = 520 nm; fluorescence was measured before and 
after lysis of the dried strip with 2 µL absolute ethanol with 
λex = 470 nm, λem = 600 nm if not stated otherwise.
Apparatus Fluorescence measurements were performed 
with a Synergy Neo 2 microplate reader from BioTek (Bad 
Friedrichshall, Germany) for fluorescence measurements 
of liposomes or with the ESEQuant LFR strip reader from 
Qiagen (Hilden, Germany) for photometric and fluorescence 
measurements of the test strips.
Results and discussion
Development of photometric and fluorescent 
liposomes
In view of a commercial application of liposomes in lateral 
flow assays, we studied modifications of previously reported 
SRB liposomes [10] on the synthesis level towards long-
term stability in solution and dehydrated on a test strip. We 
designed them for excellent photometric and fluorescent 
performance. In theory, the larger the liposome, the more 
encapsulant is present and hence can contribute to signal 
recording. Also, the small size distribution of a liposome 
population enhances their colloidal stability during long-
term storage. However, the synthesis of large unilamellar 
liposomes with small size distribution is difficult [16] and 
not that applicable to the POCT as it typically involves addi-
tional procedural steps and can become quite time-consum-
ing which rapidly increase the cost. We therefore chose the 
reverse-phase evaporation method that is known for high 
encapsulation yields followed by size extrusion to quickly 
generate differently sized liposomes in a very simple, mass-
producible manner. Furthermore, by varying the encapsulant 
concentration, we tailored the liposomes towards photomet-
ric (high SRB concentrations) or inherent fluorescent (low 
SRB concentrations that do not self-quench) detection strate-
gies. A mandatory design feature is the creation of single-
step LFA procedures to maintain the dramatic advantage 
LFAs have over other POCT systems.
Inherently fluorescent liposomes
We developed inherently fluorescent liposomes by reducing 
the amount of encapsulant dye. It is known that 150 mmol 
 L−1 SRB liposomes exhibit fluorescence self-quenching in 
their intact state [10]. Hence, high-performance fluorescence 
measurement with these liposomes is only possible through 
the release of SRB by lysis of the liposomes. Consequently, 
the fluorescence signal of such intact liposomes is typically 
below 1% of the fluorescence of its lysed pendant. While 
significant signal enhancement could be achieved, in a lat-
eral flow assay, this would be accompanied by an additional 
lysis step. Instead, liposomes which are already fluorescent 
in their intact state avoid any additional procedural step and 
are thus desirable for enhanced fluorescent LFA designs. 
Liposomes with 10, 50, and 150 mmol  L−1 SRB maintained 
Table 1  Characteristics of small sulforhodamine B liposomes (extruded through 0.2 µm membrane)
a Size by intensity of a 1:100 dilution; bIintact was obtained by diluting liposomes to 100 µmol  L−1 total lipid in HSS buffer (100 µL) and Ilysed by 
diluting the liposomes in 30 mmol  L−1 n-octyl-β-D-glycopyranoside in HSS buffer; cIintact = Iintact/Ilysed × 100, data are presented as mean ± SD 
with n = 3
Encapsulant concentration Hydrodynamic 
 diametera
(nm)




0.1 mmol  L−1 141 ± 40  − 37 ± 3 0.06 ± 0.01 0.059 ± 0.002 103 ± 4
1 mmol  L−1 136 ± 46  − 39 ± 4 0.09 ± 0.01 1.25 ± 0.03 10.5 ± 0.2
10 mmol  L−1 116 ± 51  − 32 ± 2 0.06 ± 0.01 8.1 ± 0.2 0.76 ± 0.02
50 mmol  L−1 197 ± 68  − 30 ± 2 0.10 ± 0.01 15.9 ± 0.3 0.204 ± 0.004
150 mmol  L−1 204 ± 61  − 31 ± 2 0.07 ± 0.01 39.5 ± 0.9 0.204 ± 0.005
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self-quenching. For these liposomes, the fluorescence inten-
sity of the intact liposomes remained below 1% (Tables 1 
and 2, Iintact (%)). However, the overall fluorescence per-
formance (Ilysed) of the different batches when being lysed 
continuously decreases with decreasing encapsulant concen-
trations as expected (Table 1).
Only the liposomes with 0.1 and 1 mmol  L−1 SRB showed 
increased fluorescence > 1% in their intact state, yet their 
overall fluorescence performance (Ilysed) in solution was very 
poor with as little as three orders of magnitude lower signals 
when lysed (59 RFU for the 0.1 mmol  L−1 SRB liposomes 
in comparison to the 39,500 RFU for 150 mmol  L−1 SRB 
liposomes). Thus, while the low-concentrated encapsulated 
dye prevented its self-quenching, it consequently reduced 
the obtained lysed fluorescence signal, too (Fig. 1 a). When 
using both inherent fluorescence liposomes in an interleukin 
6 LFA test (Fig. 1 b), it was found that the overall lower 
fluorescence signal outweighs the positive effect obtained 
through sensitive fluorescence detection. Specifically, con-
sistent with the observations in solution, both liposomes 
performed poorly in their fluorescent LFA. Furthermore, in 
comparison to the photometric detection of the high encap-
sulant equivalents (150 mmol  L−1), both 0.1 and 1 mmol  L−1 
SRB liposomes are by a factor of 10 less sensitive in their 
fluorescent IL-6 assay.
Optimization of photometric liposome detection
To fully harness the liposome signaling capability for the 
photometric approach, they were maximally loaded with 
SRB by increasing their size and thus the inner volume 
to increase their overall sensitivity. Furthermore, we were 
seeking to generate liposomes with small size variation to 
increase their colloidal stability during long-term storage. 
Liposomes can be synthesized using the reverse-phase evap-
oration method and extruded to a desired size range through 
various sized membranes and extrusion steps (see Table S 
1 and Fig. S 1) which is further supported by Szoka and 
colleagues [17]. Based on this information, we developed 
large liposomes in the range of 350 nm (PdI: 0.18) (Table S 
2) by extrusion through only the 1 µm membrane and small 
liposomes in the range of 190 nm (PdI: 0.07) (Table 1) by 
extrusion through 0.4 and 0.2 µm membranes with varying 
SRB encapsulation concentrations. These liposomes showed 
in initial characterizations that the larger the liposome and 
the higher the SRB concentration is, the more SRB is 
Table 2  Overview of 
fluorescence intensities of large 
and small sulforhodamine B 
liposomes
a 350 nm liposomes; bIintact was obtained by diluting liposomes to 100 µmol  L−1 total lipid in HSS buffer 
(100 µL) and Ilysed by diluting the liposomes in 30 mmol  L−1 n-octyl-β-D-glycopyranoside in HSS buffer; c
Iintact = Iintact/Ilysed × 100; d190 nm liposomes, data are presented as mean ± SD with n = 3








10 mmol  L−1 12.5 ± 0.5 0.66 ± 0.03 10 mmol  L−1 8.1 ± 0.2 0.76 ± 0.02
50 mmol  L−1 49.3 ± 0.9 0.259 ± 0.005 50 mmol  L−1 15.9 ± 0.3 0.204 ± 0.004
150 mmol  L−1 66 ± 1 0.152 ± 0.002 150 mmol  L−1 39.5 ± 0.9 0.204 ± 0.005
Fig. 1  Fluorescence performance of large and small liposomes with 
varying encapsulation concentrations. a Fluorescence performance of 
intact and lysed large and small liposomes in solution of 100 µL lipo-
some dilution (c (total lipid) = 100 µmol  L−1) in HSS buffer (intact) 
or 30  mmol  L−1 n-octyl-β-D-glucopyranoside in HSS buffer (lysed) 
and b fluorescence performance of intact small 0.1 and 1 mmol  L−1 
SRB liposomes in an IL-6 LFA, data are presented as mean ± SD 
(error bar) with n = 3; fluorescence signal was recorded with 
λex = 550 nm, λem = 600 nm
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encapsulated within the liposome, as evidenced by the fluo-
rescent measurement of lysed liposomes (Ilysed) (Table 2). As 
these small and large 150 mmol  L−1 SRB liposomes yielded 
the strongest fluorescence signal and are easy to manufac-
ture, these two types of liposomes were chosen to evaluate 
their tolerance towards antibody coupling and dehydration 
and determine their overall performance in a regular LFA. 
Even larger liposomes could be investigated in the future; 
however, based on prior experiences (data not shown), it is 
assumed that more steric hindrance and less colloidal stabil-
ity could hamper large liposomes.
Photometric and fluorescence lateral flow 
immunoassay
Previously optimized conditions for coupling streptavidin 
to liposomes were not directly transferrable to IgG coupling 
[15]. Thus, we used the relatively inexpensive anti-digox-
igenin IgG (< Dig >) to identify the ideal coupling ratio 
of 1:17:42:0.17 (n(COOH):n(EDC):n(NHS):n(antibody)) 
and obtained already in this experiment a 4-times steeper 
slope and an order of magnitude lower detection limit of 
1 ng  mL−1 vs.10 ng  mL−1 with our liposome approach in 
contrast to commercial AuNPs (Online Resource 1 – ESM 
2.3, Fig. S 2).
These coupling conditions were subsequently used for 
the covalent attachment of anti-interleukin 6 (< IL-6 >) 
to the liposomes using a coupling ratio of 1:17:42:0.017 
(n(COOH):n(EDC):n(NHS): n(antibody)) for anti-inter-
leukin 6 (< IL-6 >). Two different antibodies were tested, 
where one antibody showed an over 10-times higher sensi-
tivity with over 20-times stronger signals especially for low 
concentrations (data not shown) which was consequently 
used in the following experiments.
In the end, small and large liposomes were coupled 
accordingly to clone 2 (< IL-6 >) and tested in the IL-6 
LFA format towards the standard colloidal gold approach 
as illustrated in Fig. 2. For the determination of the LOD, 
yLOD = initial value (A1) + 3 × standard deviation of the blank 
 (SDblank) was chosen as it yields a more realistic LOD in 
contrast to the often-used linear approach. Already the small 
liposomes showed here significant improvement of the LOD 
with 4 pg  mL−1 IL-6 in comparison to colloidal gold with 
an LOD of 0.025 ng  mL−1 when detected photometrically 
(Fig. S 5) with similar resolution  (slope190 nm = 0.7 mL  pg−1, 
 slopecolloidal gold = 0.5 mL  pg−1). Switching to large liposomes 
showed sensitivity enhancement not only by an even lower 
LOD (1 pg  mL−1) but also a significantly increased slope 
of 3.4 mL  pg−1 (Fig. S 5) was obtained, which is due to 
the increased inner volume of the liposomes and thus 
elevated amount of dye present (slopes were determined 
from the linear region). Furthermore, the large liposome 
approach had a dynamic range of almost three orders 
of magnitude. Even when measured photometrically in 
serum, the liposomes outperform commercial colloidal 
gold with slightly increased LOD towards the buffer con-
ditions  (LOD190 nm = 23 pg  mL−1,  LOD350 nm = 7 pg  mL−1, 
 LODcolloidal gold = 81 pg  mL−1) (Fig. 3 a).
Since the strategy to achieve a lower LOD using inher-
ently fluorescent liposomes was not successful, a system 
was developed in which liposomes were bound to test, and 
control lines were lysed through an additional step in order 
to harness their superior fluorescent capability. In addi-
tion, pretests in a microtiter plate approach showed that the 
well-known fluorescence enhancement of SRB in human 
serum [18] could assist in enhancing the sensitivity (Online 
Resource 1 – ESM 2.4, Fig. S 3, Table 3). Yet, with the 
current assay design, it is not possible to take advantage 
of this in the LFA format (Fig. S 4). We assume that this 
is due to the absence of a bulk aqueous enviroment on the 
test strip which does not allow for a polarity change when 
introducing HSA into the system. Furthermore, surpris-
ingly, the fluorescence approach did not yield a lower LOD 
(0.2 ng  mL−1) in contrast to the photometric approach. This 
is most likely due to the high background signal and the 
inherently introduced error of the additional procedural 
steps. The background signal can be lowered by changing 
the assay procedure and preapplying the liposomes to the 
conjugate pads. However, as can be seen in Fig. 3, the lack 
in preincubation time compensates any benefit obtained 
through lower background signals. Specifically, it led to an 
increased LOD not only with the liposomes but also with the 
AuNP (0.1 ng  mL−1) (Fig. 3 b). In the future, other mem-
brane materials that allow for more interactions such as slow 
running membranes (CN150) (Fig. S 6) will be investigated 
along with developing an effective dehydration strategy for 
Fig. 2  Illustration of applied analysis principle of developed interleu-
kin 6 lateral flow assay
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the large liposomes. When referencing to already published 
articles, our results are impressive as we show here sev-
eral versions of LFA procedures that can be operated with 
undiluted real-world samples and yield already in its easi-
est form (photometrically) exceptional sensitivity with only 
36 µL sample volume, whereas in literature often samples 
with only 10% serum as matrix were employed, and typi-
cally more sample volume is needed (Table 3). Overall, only 
a few articles are published which developed LFA-based 
IL-6 detection (Table 3), and most of them are limited to 
academic studies only and require sophisticated detection 
devices. Here, on the contrary, a commercially ready system 
was used and enhanced by refined liposomal reporter probes 
which, similarly to AuNP, can be used for a multitude of 
immune-LFAs. Already the photometric readout competes 
with the sensitivity of most of the reported LFAs and the 
commercial colloidal gold approach. We envision simulta-
neous photometrical or fluorescent application in the future 
providing LODs in the LFA format that can rival signal gen-
eration in microtiter plate assays.
In order to render a truly universal liposome label 
approach, we compared directly coupled < IL-6 > liposomes 
to those indirectly coupled to streptavidin-coated liposomes 
via < IL-6 > -biotin. Such a universal reporter probe bypasses 
stability issues typically encountered with antibodies extend-
ing the overall shelf life of this reagent. We obtained no 
significant difference between the two strategies, as similar 
signal intensities, equal slopes  (slopeindirect: 1.046 mL  ng−1, 
 slopedirect: 1.069  mL   ng−1) and sensitivities  (LODdirect: 
0.019 ng  mL−1,  LODindirect: 0.026 ng  mL−1) were obtained 
with the direct and indirect approaches (Fig. 4).
Stability study and liposome dehydration
Since the direct and indirect coupling approach performed 
similarly in the assay, the stability study was conducted with 
streptavidin-modified liposomes. In the end, these would be 
favored over the direct coupling approach in a commercial 
application as they can function as a generic label. These 
universal streptavidin-modified liposomes that are independ-
ent from the durability of the antibody itself were used in a 
long-term stability study assessing their stability in solution 
as well as in dehydrated form on the conjugate pad. Testing 
was conducted in a simple streptavidin–biotin assay with 
the small (190 nm) streptavidin-modified liposomes. These 
liposomes remained stable in solution for at least 12 months 
at 2–8 °C and even 2 months at elevated temperatures up 
to 39 °C (Fig. 5 a). The results from such an accelerated 
stability study translate roughly into 8 years when stored at 
4 °C [26].
Dehydration of the liposomes onto the conjugate pad 
was mainly motivated by the desire to reduce the number of 
assay steps and reagents needed to perform a LFA. In a first 
attempt, we identified the most suitable conjugate pad mate-
rials by simply drying our liposomes on different pad materi-
als in HSS buffer at room temperature and 50% air humidity 
for 1 h. The liposomes retained approximately 80% of the 
liquid signal when dried on the conjugate pad made of fiber 
glass with binder (Fig. 6), whereas all other pad materials 
studied showed meager performance (recovery < 50%). As 
manufacturers frequently pretreat membranes and pad mate-
rial with inter alia detergents and typically use confidential 
binder formulations, this observation is not surprising and 
Fig. 3  Titration of IL-6 with large and small liposome conjugates 
benchmarked to colloidal gold. a Photometric detection in human 
serum and b fluorescence detection of liposomes after lysis in 
human serum benchmarked to colloidal gold (photometric detec-
tion). In a, preincubation of liposomes (5  min) with IL-6 and anti-
IL-6-biotin IgG in running solution; in b, liposomes on conjugate 
pad without preincubation. Photometric measurement was done at 
λmax = 520  nm; fluorescence signal was recorded with λex = 470  nm, 
λem = 600 nm; data are presented as mean ± SD (error bar) with n = 3; 
four-parameter logistic fitting with Origin2020 was done within a 
R2 = 0.9940 (red), R2 = 0.9687 (blue), and R2 = 0.9557 (black) and in 
b R2 = 0.9493 (red) and R2 = 0.9583 (blue), yLOD = A1 + 3  SDblank
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rather emphasizes the need for prescreening of LFA materi-
als within the development process. For the follow-up long-
term stability study, liposomes were dispensed on the fiber 
glass conjugate pad with binder and dried in a drying cabinet 
at 37 °C for 1 h. After assembling, the test strips were stored 
at 2–8 °C, 18–25 °C, and at 35–39 °C and tested periodi-
cally to assess the reduction in the response. The test strips 
remain stable for at least 9 months at temperatures between 
2 and 25 °C with no significant reduction in the initial sig-
nal response and only a minor signal drop (< 10%) when 
retested after 13 months (Fig. 5 b).
Harrigan and colleagues [27] stated that the stability of 
vesicles critically depends on the vesicle size with the result 
that smaller systems are most stable. We made similar obser-
vations, as currently only the small liposomes straightfor-
wardly tolerate the dehydration process and were hence used 
for the long-term stability study. Dehydration of the large 
liposomes is currently under investigation as present data 
indicates that the liposomes are not fully destroyed (data not 
shown). Optimization of the drying conditions most likely 
provides the desired remedy, where we will apply protect-
ing sugars as suggested previously by Martorell and col-
leagues [28]. They observed decreased recoveries for the 
larger liposomes as well but to a lesser extent (approx. 60% 
in contrast to 75% recovery with small liposomes). The 
Table 3  Recently published techniques for sensitive detection of interleukin 6 with immuno-LFAs
a Europium(III) chelate–doped nanoparticles; bmolecular weight of 21 kDa for IL-6 was presumed; cup-converting phosphor nanoparticles; dsur-
face enhanced Raman scattering: ecore functionalized with Raman-active 4-nitrothiophenol for IL-6 or thio-2-naphthol for IL-8; fFluoSpheres®; 
fluorophore-doped particles (200 nm); gIRDye 800CW (Li-Cor Biosciences)
Detection method LOD Matrix Special remarks Ref
Fluorescence
(Eu-NPa)
0.37 pg  mL−1 Buffer, human serum 70 µL sample





100 pM (2.1 ng  mL−1)b Buffer, 10% serum LFA run 20 min
100 µL sample, multiplex, pro-








Au/Au core satellite 
 nanoparticelse
n. a PBS Proof of principle, multiplex, 
























Buffer, 100% human serum (HS) 36 µL sample







Buffer, 100% human serum (HS) 36 µL sample
LFA run 15 min, commercial 
strip reader
This work
Fig. 4  Performance test of universal streptavidin-modified liposomes 
towards direct-coupled small liposomes with anti-interleukin 6 IgG 
(< IL-6 >), four-parameter logistic fit with R2 = 0.9970 (black) and 
R2 = 0.9993 (red). Fifty microliters of a mixture of IL-6 and liposomes 
(40 mOD per test) in running solution were applied to the test strip 
(< IL-6 > test line), test run for 15  min. Streptavidin-liposomes were 
mixed with anti-IL-6-biotin (equaling 0.2  µg anti-IL-6-biotin per test) 
and IL-6; photometric measurement was done at λmax = 520 nm; data are 
presented as mean ± SD (error bar) with n = 3,  yLOD = A1 + 3 ×  SDblank; 
slope derived from four-parameter logistic fit function
Highly sensitive interleukin 6 detection by employing commercially ready liposomes in an LFA…
1 3
results are not directly comparable as support material and 
size determination vary but it points to prosper when refining 
the dehydration conditions for our large liposomes.
Conclusion
The established commercial LFA system with colloidal gold 
for the detection of IL-6 shows already good sensitivity with 
0.025 ng  mL−1. However, by replacing the gold nanoparti-
cles with refined dye–loaded liposomes, we were able to 
improve the sensitivity by over one order of magnitude to 
just 1 pg  mL−1 with simple photometric detection. Further-
more, utmost care was taken to ensure that the liposomes 
are easily mass-producible, could be dehydrated on the LFA 
membrane itself, and hence could be applied in the same, 
straightforward, simple, and easy-to-use LFA strategy that 
is so desirable. Further improvement of the LOD through 
fluorescent detection approaches, however, is not as easy 
to accomplish. Inherently, fluorescent liposomes do not 
provide enough signal intensity and those that require an 
additional process step, as the dye has to be released from 
the liposome prior to detection, unfortunately compensate 
any gained signal intensity at the LOD by higher background 
signals and less reproducibility due to the additional assay 
steps. Thus, while in a refined environment such as a micro-
titer plate, improved LODs can be obtained through fluo-
rescence detection of these liposomes; this is not as easily 
translated to a robust, commercially ready LFA approach. 
More experiments are needed to lower background signals, 
improve analyte-liposome interactions, and hence lower the 
LOD effectively. However, already now the increased signal 
intensity afforded by the fluorescent liposomes will assist 
in the development of less sophisticated detection devices. 
Fig. 5  Long-term stability of small streptavidin-liposomes in solu-
tion a or dehydrated on a test strip b before test run on LFA strips 
with biotin test line; red line indicates initial response at time point 
zero. Liposomes were diluted to 25 mOD per test in 90 µL a, test run 
for 5 min; in b, liposomes with 25 mOD per test were dehydrated on 
test strip and rehydrated by 50 µL running buffer, test run for 15 min. 
Photometric measurement was done at λmax = 520  nm; data are pre-
sented as mean ± SD (error bar) with n = 5; times marked with an 
asterisk equals triplicates, reference line indicates initial response
Fig. 6  Evaluation of different conjugate pad materials for small lipo-
some conjugates a obtained signal intensities and b real images. Test 
strips were prepared with 5 µL liposome dilution in conjugate pad 
buffer (80 mOD per test); test run for 5 min in 100 µL running buffer; 
photometric measurement was done at λmax = 520  nm; data are pre-
sented as mean ± SD (error bar) with n ≥ 2
 Rink S. et al.
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Expanding on the applicability of these new reporter probes, 
our universal liposomes, which maintain sensitivity levels of 
directly conjugated liposomes, show remarkable long-term 
stability when stored in solution and dehydrated on a test 
strip of at least 1 year. These adaptable liposomes can easily 
be transferred to any other analyte of interest manifesting 
them as a true alternative to standard colloidal gold. With 
this, a highly flexible and supersensitive toolset is provided 
for tailored assay development. Furthermore, in light of the 
importance of IL-6 detection with infectious diseases such 
as COVID-19, the here presented liposome-based LFA indi-
cates that liposomes will rival the prevalence of colloidal 
gold as a benchmark in LFA analysis.
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